The effects of maternal depression and maternal selective serotonin reuptake inhibitor exposure on offspring by J. D. A. Olivier et al.
REVIEW ARTICLE
published: 21 May 2013
doi: 10.3389/fncel.2013.00073
The effects of maternal depression and maternal selective
serotonin reuptake inhibitor exposure on offspring
J. D. A. Olivier 1,2*, H. Åkerud1, H. Kaihola1, J. L. Pawluski3, A. Skalkidou1, U. Högberg1 and
I. Sundström-Poromaa1
1 Department of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden
2 Center for Gender Medicine, Karolinska Institutet, Stockholm, Sweden
3 GIGA-Neurosciences, University of Liège, Liège, Belgium
Edited by:
Judith Homberg, Radboud
University Nijmegen Medical
Centre, Netherlands
Reviewed by:
Tim Oberlander, Brain Research
Center, Canada
Hanan El Marroun, Erasmus Medical
Centre, Netherlands
*Correspondence:
J. D. A. Olivier, Kvinnoklin.
forskingslab, Department of
Women’s and Children’s Health,
NBV Uppsala University Hospital,
Uppsala University, SE-75185
Uppasala, Sweden.
e-mail: jocelien.olivier@kbh.uu.se
It has been estimated that 20% of pregnant women suffer from depression and it is
well-documented that maternal depression can have long-lasting effects on the child.
Currently, common treatment for maternal depression has been the selective serotonin
reuptake inhibitor medications (SSRIs) which are used by 2–3% of pregnant women
in the Nordic countries and by up to 10% of pregnant women in the United States.
Antidepressants cross the placenta and are transferred to the fetus, thus, the question
arises as to whether children of women taking antidepressants are at risk for altered
neurodevelopmental outcomes and, if so, whether the risks are due to SSRI medication
exposure or to the underlying maternal depression. This review considers the effects
of maternal depression and SSRI exposure on offspring development in both clinical
and preclinical populations. As it is impossible in humans to study the effects of SSRIs
without taking into account the possible underlying effects of maternal depression (healthy
pregnant women do not take SSRIs), animal models are of great value. For example,
rodents can be used to determine the effects of maternal depression and/or perinatal SSRI
exposure on offspring outcomes. Unraveling the joint (or separate) effects of maternal
depression and SSRI exposure will provide more insights into the risks or benefits of SSRI
exposure during gestation and will help women make informed decisions about using
SSRIs during pregnancy.
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The number of women using selective serotonin reuptake
inhibitors (SSRIs) during pregnancy is increasing, although
knowledge on long-term neurodevelopmental effects to the child
is lacking. This review summarizes clinical and preclinical find-
ings of how SSRI exposure during pregnancy affects child out-
comes. Many clinical findings parallel aspects of the preclinical
data, such as decreased gestational length, birth weight, pain
responses, and social behavior, increased spontaneous abor-
tion/mortality rate, risk of cardiac anomalies, anxiety, depres-
sion, and rapid eye movement (REM) sleep, and affected 5-HT
metabolism, motor development, and hypothalamic-pituitary-
adrenal (HPA) stress reactivity. However, antenatal depression
also has been associated with long-term neurodevelopmental out-
comes. This review therefore starts by describing effects on the
offspring exposed to antenatal depression and will then focus on
outcomes of SSRI exposure during pregnancy.
MATERNAL DEPRESSION
Women are at an increased risk of becoming depressed during
pregnancy and in the postpartum period, especially when they
have pre-existing psychiatric illnesses. In fact, depressive symp-
toms may occur more frequently during pregnancy than in the
postpartum period (Suri et al., 2007). During pregnancy, ∼20%
of women report symptoms of depression (Patkar et al., 2004),
and 4–7% of pregnant women suffer from major depressive dis-
order (Andersson et al., 2003; Gorman et al., 2004; Melville et al.,
2010). Among women who experience postpartum depression,
nearly 40% develop their symptoms during pregnancy (Johnson,
1997). Biological and psychosocial factors, such as the genetic
setup of the mother, hormonal/reproductive history, current
stressors, and life experiences, are known to be risk factors for
development of antenatal depression (Miller and LaRusso, 2011).
Antenatal depression has been associated with higher rates of
poor pregnancy outcomes (such as pre-eclampsia and premature
delivery), impaired fetoplacental function, decreased fetal growth,
and neonatal complications (Orr and Miller, 1995; Kurki et al.,
2000; Bonari et al., 2004; Jablensky et al., 2005; Wisner et al.,
2009; ElMarroun et al., 2012). However, while premature delivery
and decreased fetal growth are established outcomes of antenatal
depression (Henrichs et al., 2010), the influence is most pro-
found in low-income countries and countries with great health
inequalities (Grote et al., 2010). Antenatal depression is also asso-
ciated with poor nutrition, obesity, smoking, alcohol, and drug
abuse which all can have negative effects on the developing child
(Andersson et al., 2004; Bonari et al., 2004).
Several neurodevelopmental outcomes have been reported in
children exposed to antenatal or postpartum depression. While
it has long been known that postpartum depression is associated
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with poor maternal-child attachment with long-term repercus-
sions (Murray and Cooper, 1997), fewer studies have addressed
the effects of antenatal depression. DiPietro et al. (2006) reported
that antenatal depression improved the mental and motor devel-
opment in 2-year-old children, indicating that moderate amounts
of maternal adversity may optimize early child development.
However, most other studies have found negative associations
between antenatal depression and neurodevelopmental outcomes
in children. For instance, antenatal depression has been associ-
ated with developmental delays in 18-month-old children (Deave
et al., 2008), increased behavioral and emotional problems in
4-year-old children (O’Connor et al., 2002), increased anxiety in
6- to 9-year-old children (Davis and Sandman, 2012), and atten-
tion problems in children aged 3 and 4 (Van Batenburg-Eddes
et al., 2012). Later on, also gender-related offspring effects have
been reported. Hay et al. (2008) tested the effects of antenatal and
postpartum depression on children’s outcomes during adoles-
cence and found that 42% of the antenatally depression-exposed
and 46% of the postpartum depression-exposed adolescents dis-
played emotional disorders. Interestingly, the association between
antenatal depression and emotional disorders was only sig-
nificant in adolescent girls. Parenthetically this gender-related
offspring differences hold true for postpartum depression as
well. Following exposure to maternal postpartum depression
increased internalizing and externalizing problems in 12-year-
old children have been reported (Agnafors et al., 2012), where
girls expressed more internalizing problems, and boys expressed
more externalizing problems. Hay et al. (2008) conclude that
the greater the extent of exposure to maternal depression, the
more likely it was for the child to develop a broader range of
problems.
It should also be emphasized that paternal depression is of
relevance for offspring developmental outcomes. Paulson et al.
(2009) studied language development in children whose mother
or father were depressed 9 and 24 months after birth. Depressive
symptoms in either the mother or the father lowered the fre-
quency of reading to their child. However, only fathers’ depression
predicted lower frequencies of reading to the child at the age
of 24 months and reduced expressive language at the age of
2 years. Furthermore, van den Berg et al. (2009) showed that
paternal depression also has an influence on excessive infant
crying.
Thus, antenatal maternal depression poses a threat to mater-
nal both well-being and healthy development in the off-
spring. These effects are likely due to a number of factors
such as the physiology of the intrauterine environment, peri-
natal maternal and paternal mood disorders, current stres-
sors, social support, timing, intensity, and genetic background.
Therefore, understanding the influence of antenatal depres-
sion during pregnancy on child outcomes is rather complex.
Incorporating methods of studying the fetus that has been
exposed to antenatal depression provides the opportunity to
examine the intrauterine milieu as the developmental niche of
the fetus and will help us to unravel the mechanisms under-
lying maternal psychological factors that may have long-lasting
developmental effects (DiPietro, 2012; Sandman and Davis,
2012).
ANTIDEPRESSANT MEDICATION USE DURING PREGNANCY
Continuing or starting pharmacological therapy during preg-
nancy is often unavoidable. Cohen et al. (2006) showed that
68% of depressed women who discontinued treatment relapsed
during pregnancy, while only 26% of those who continued treat-
ment did so. Currently, 1–3% of pregnant women in Europe
are using antidepressant medications (El Marroun et al., 2012;
ADs; Kieler, 2012), while user frequencies in the U.S. are 4–13%
(Cooper et al., 2007; Hayes et al., 2012). Twenty-five percent of
women on antidepressants continue treatment during pregnancy
and 0.5% of pregnant women who have not been treated with
antidepressants previously begin treatment (Ververs et al., 2006).
As antidepressant medications cross the placenta and are evident
in breast milk, questions have been raised about their develop-
mental safety (Heikkinen et al., 2003; Noorlander et al., 2008).
However, exposure to antenatal depression similarly increases the
risk of child psychopathology (affective, anxiety, and disruptive
behavior disorder;Weissman et al., 2006). Therefore, the question
arises as to whether children exposed to maternal antidepressants
are at risk and, if so, whether the risks are due to medication or to
the underlying depression.
SELECTIVE SEROTONIN REUPTAKE INHIBITORS
SSRIs are the most widely prescribed antidepressants worldwide
because of their efficacy, relatively few (adverse) side-effects, and
therapeutic safety (Barbey and Roose, 1998). SSRIs do not cause
gross structural neuroteratogenic effects and are often considered
to be safe for antenatal use (Gentile, 2005). Therefore, prescrip-
tion of SSRIs during pregnancy, to promote the psychological
health of the mother, has increased (Oberlander et al., 2006).
By blocking the serotonin transporter (5-HTT) SSRIs inhibit the
reuptake of serotonin (5-HT) into presynaptic nerve terminals
resulting in an increase in the synaptic concentration of 5-HT
(see Figure 1). During adulthood 5-HT mainly acts as a mod-
ulatory neurotransmitter regulating emotion, stress responses,
arousal, sleep, learning, cognition, and attention. However, dur-
ing brain development 5-HT also acts as a neurotrophic factor,
regulating cell division, differentiation, migration, growth cone
elongation, myelination, synaptogenesis, and dendritic pruning
(Gaspar et al., 2003). Thus, changes in the 5-HT levels during
neurodevelopment have the potential to affect a number of pro-
cesses (Ansorge et al., 2007). While human studies are hampered
by time and ethical constraints, animal models offer the possi-
bility to study both the short- and long-term consequences of
maternal SSRI exposure. Therefore, both clinical and preclinical
data on the effects of maternal SSRI exposure on the offspring are
described in this review.
CLINICAL FINDINGS
Antidepressants are able to cross the placenta and relevant con-
centrations have been detected in umbilical vein blood (Hendrick
et al., 2003b). Fluoxetine and citalopram have a high ratio of
umbilical vein-to-maternal serum concentration, while sertraline
and paroxetine have a low ratio. Maternal plasma levels of fluoxe-
tine and its metabolite, norfluoxetine, decrease drastically during
pregnancy (Heikkinen et al., 2003), probably due to the nor-
mal physiological changes during pregnancy. At birth, neonatal
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FIGURE 1 | Schematic figure of the serotonergic neuron in a normal
situation (left) and when exposed to SSRIs (right). Upon neuronal
activation 5-HT (red dots) is being released in the extracellular cleft,
activating receptors (blue) at the postsynaptic neuron. To end the signal,
excessive 5-HT is being re-uptaken by the serotonin transporter (green)
from the extracellular cleft into the presynaptic neuron. In the presynaptic
neuron 5-HT is degraded and/or stored in vesicles for future release. In the
picture on the right, the serotonin transporter has been blocked by a SSRI
and is no longer capable to reuptake 5-HT in the presynaptic neuron,
increasing the 5-HT in the extracellular cleft.
plasma levels of fluoxetine and norfluoxetine have been shown to
be 65 and 72% of the maternal levels (Heikkinen et al., 2003).
Pregnancy complications
Twometa-analyses have revealed that SSRIs and other antidepres-
sant medications may increase the risk of miscarriage (Hemels
et al., 2005; Rahimi et al., 2006). However, this may not always
be the case (reviewed in Ellfolk and Malm, 2010), while a recent
meta-analysis showed only a borderline association (Ross et al.,
2013). Women continuing SSRI use after the first trimester also
have an increased risk of preeclampsia compared with women
who discontinue treatment or non-users (Qiu et al., 2009; Toh
et al., 2009b; Reis and Källén, 2010). Recently, Palmsten et al.
(2012) found that the risk of developing preeclampsia was similar
in non-depressed and depressed women (2.3 and 2.4%, respec-
tively). Furthermore, compared to depressed women, the relative
risk of preeclampsia after SSRI exposure in GW10 and 20 was
3.3 for monotherapy and 4.5 for polytherapy [and even greater
for selective noradrenalin reuptake inhibitors (SNRI) and tricyclic
antidepressants (TCA)]. In conclusion, antidepressant use during
pregnancy increases the risk of preeclampsia, with modest effects
after use of SSRIs and much higher effects after use of SNRIs and
TCAs.
Pregnancy outcomes
As with maternal antenatal depression, SSRI use during preg-
nancy has often been associated with increased rate of preterm
birth (Chambers et al., 1996; Costei et al., 2002; Simon et al., 2002;
Källén, 2004; Wen et al., 2006; Davis et al., 2007; Lund et al., 2009;
Wisner et al., 2009; Reis and Källén, 2010; Yonkers et al., 2012),
decreased birth weight (Chambers et al., 1996; Källén, 2004; Wen
et al., 2006), being born small for gestational age (Oberlander
et al., 2006; Toh et al., 2009a), and reduced fetal head growth (El
Marroun et al., 2012). However, several studies did not find an
effect of SSRIs on preterm birth (Kulin et al., 1998; Ericson et al.,
1999; Suri et al., 2004; Malm et al., 2005; Oberlander et al., 2006;
Toh et al., 2009a) and birth weight (Ericson et al., 1999; Suri et al.,
2004; Malm et al., 2005; Lund et al., 2009; Reis and Källén, 2010).
Nevertheless, an inverse relationship was found between lower
gestational age and high doses of SSRIs in late pregnancy (Suri
et al., 2007). Several theories have been postulated for low birth
weight after exposure to SSRIs; for example, fluoxetine reduces
maternal appetite and weight gain, which may affect fetal growth
(Chambers et al., 1996). However, other SSRIs have been asso-
ciated with weight gain, rather than weight loss. Another theory
is that the altered 5-HT levels, caused by SSRIs use, increase the
risk of intrauterine growth retardation and preterm delivery by
impairing placental blood flow (Wen et al., 2006). Whether or not
these factors play a role in gestational age and weight remains to
be elucidated.
Umbilical cord blood monoamine and metabolite concentrations
SSRI treatment during pregnancy reduces whole blood 5-HT
(−69%), 5-hydroxyindoleacetic acid (−18%; 5-HIAA; main
metabolite of 5-HT) and homovanillic acid (−23%; a major
catecholamine metabolite) concentrations in the umbilical vein
(Laine et al., 2003). In infants, lower 5-HIAA concentrations
are inversely correlated with 5-HTergic symptom scores (such as
myoclonus, restlessness, tremor, shivering, hyperreflexia, incoor-
dination, and rigidity) and there is a positive correlation between
cerebrospinal fluid and peripheral blood 5-HT/metabolite con-
centrations (Sarrias et al., 1990). This suggests an association
between the central 5-HTergic effects and the cord blood 5-
HIAA concentration. Similarly, plasma levels of noradrenalin
were decreased in the umbilical vein of SSRI-exposed infants and
there was also a tendency for reduced dihydroxyphenylglycine
(DHPG; group I metabotropic glutamate receptor selective ago-
nist) and 3,4-Dihydroxyphenylacetic acid (DOPAC; metabolite
of dopamine) in SSRI-exposure infants (Laine et al., 2003). Not
surprisingly, pharmacokinetic differences exist between antide-
pressants. DHPG concentrations were significantly lower (−40%)
in fluoxetine-exposed infants compared with citalopram-exposed
infants. This effect may be due to the lower affinity of citalo-
pram, compared to fluoxetine, for the noradrenaline reuptake
pump (Hyttel, 1994). On the other hand, citalopram, but not flu-
oxetine, significantly reduces cord blood DOPAC concentrations
compared with controls. Thus, maternal use of SSRIs induces
significant changes in the cord blood 5-HT and metabolite con-
centrations. However, it remains to be determined how these
changes in 5-HT and its metabolite impact the outcome of the
offspring.
Neonatal adaptation
In the first 2 weeks after birth up to 30% of antenatal
SSRI-exposed neonates display poor neonatal adaption such
as respiratory distress, temperature instability, feeding difficul-
ties, jitteriness, irritability, sleep problems, tremors, shivering,
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restlessness, convulsions, rigidity, hypoglycaemia, and jaundice
(Chambers et al., 1996; Cohen et al., 2000; Costei et al., 2002;
Casper et al., 2003; Laine et al., 2003; Källén, 2004; Oberlander
et al., 2006; Davis et al., 2007). These effects occur more often
in neonates who were exposed to SSRIs in late pregnancy, and
symptoms arise earlier and more often in neonates exposed to
higher SSRI doses (Costei et al., 2002; Källén, 2004; Davis et al.,
2007). A dose-response effect of paroxetine on neonatal adapta-
tion problems has been reported (Levinson-Castiel et al., 2006)
with higher doses of paroxetine being related to greater neona-
tal adaptation problems. In addition to the dose, the duration of
SSRI exposure plays a significant role on neonatal outcomes with
respiratory distress being linked to longer prenatal SSRI expo-
sure (Oberlander et al., 2008c). It is unclear whether the neonatal
adaptation symptoms are a result of neonatal withdrawal from
the SSRIs or overstimulation of the 5-HTergic system (Isbister
et al., 2001). Nevertheless, these symptoms are usually mild and
disappear 2 weeks postpartum (Moses-Kolko et al., 2005).
Another way to measure neonatal adaptation is to measure
gross outcome markers such as Neonatal Intensive Care Unit
(NICU) admission and neonatal seizures. Several studies report
an increased risk of neonatal seizures, longer hospital stays, and
NICU admissions after SSRI use during pregnancy (Simon et al.,
2002; Källén, 2004; Lattimore et al., 2005; Oberlander et al.,
2006; Wen et al., 2006; Cole et al., 2007; Davis et al., 2007),
although an increased risk for NICU admissions have also been
found after prenatal depression (Chung et al., 2001). Malm et al.
(2005) found that 11.2% of neonates exposed to SSRIs in the
first trimester and 15.7% of infants exposed to SSRIs during the
third trimester of pregnancy were treated in specialized or inten-
sive care units. There is also a 2- to 8-fold increase risk for low
Apgar scores in SSRI-exposed neonates (Källén, 2004; Lund et al.,
2009; Wisner et al., 2009). Neonates of depressed mothers also
often display low Apgar scores (Wisner et al., 2009). Therefore, it
is difficult to disentangle whether the low Apgar scores and NICU
admissions are due to the SSRI exposure or to the underlying
depression.
Congenital malformations in the neonate
SSRI use during pregnancy may increase the risk for congenital
malformations and cardiac anomalies. A Danish study reported
that 4.9% of infants exposed to SSRIs during the first trimester
of pregnancy, and 6.8% exposed to SSRIs during late pregnancy
display congenital malformations, while corresponding the fig-
ure in non-exposed infants was 3.4% (Wogelius et al., 2006).
Chambers et al. (1996) found more minor anomalies in infants
exposed to SSRIs during the first trimester of pregnancy com-
pared with non-exposed infants, while no differences were found
in the number of major anomalies. Alwan et al. (2007) report
that first trimester SSRI exposure increases the risk for anen-
cephaly, craniosynostosis, and omphalocele. Louik et al. (2007)
also found an increased risk for omphalocele and for septal defects
after first trimester exposure to sertraline and an association
between paroxetine exposure and right ventricular outflow tract
obstruction defects. Moreover, sertraline was associated with anal
atresia and limb-reduction defects and paroxetine was associ-
ated with neural tube defects, club foot, and undescended testes
(Louik et al., 2007). Cardiac malformations were also reported
by Malm et al. (2005) and Diav-Citrin et al. (2008), who found
a 3- to 4-fold increased in cardiac malformations in infants of
fluoxetine-exposed women. However, there are also several stud-
ies that do not report an association with maternal prenatal SSRI
exposure and neonatal congenital malformations (Altshuler et al.,
1996; Ericson et al., 1999; Simon et al., 2002; Hendrick et al.,
2003a; Einarson and Einarson, 2005; Källén and Otterblad, 2007).
Overall, the effects of prenatal SSRI exposure on congenital mal-
function appear small and seem to be most apparent when SSRIs
are used in the first trimester of pregnancy. However, the effects of
prenatal SSRIs on congenital heart disease becomes more severe if
SSRIs are taken with other medications, such as benzodiazepines
(Oberlander et al., 2008d).
Persistent pulmonary hypertension in the neonate
In the condition of persistent pulmonary hypertension (PPHM)
the pulmonary vasculature fails to relax after birth, which results
in hypoxemia. The occurrence of PPHN is ∼0.2% in live-born
infants and it is associated with substantial infant mortality
and morbidity. Several studies have shown an increased risk
for PPHM in SSRI-exposed infants. Exposure during the first
trimester (Källén and Olausson, 2008), as well as during late
pregnancy (Chambers et al., 1996, 2006), significantly increases
the risk for PPHM. This result was confirmed in a large Nordic
study, where the risk for PPHM in neonates after SSRI exposure
was shown to be at least doubled (Kieler, 2012). However, sev-
eral studies did not find any association between prenatal SSRI
use and PPHM (Andrade et al., 2009; Wichman et al., 2009;
Wilson et al., 2011). Moreover, both maternal depression and
SSRI usage have been linked to increased risk of premature birth
(Wisner et al., 2009), with the risk of PPHN being four times
higher in babies born at 34–36 weeks compared to those with full-
term gestation (Källén and Otterblad, 2007; Hibbard et al., 2010).
Therefore, it is difficult to state whether maternal SSRI exposure
truly increases the risk for PPHM, or if other, secondary, factors
contribute to the increased risk for PPHM.
Neurodevelopmental outcomes
Within the first week after birth, infants are exposed to a routine
heel lance (blood sampling for screening of metabolic diseases).
Oberlander et al. (2002) used this acute noxious event to study
the effect of maternal SSRI exposure on neonatal responses to
pain. In response to the heel lance, SSRI-exposed newborns show
significantly less facial activity and a reduced heart rate, indi-
cating that prenatal exposure to SSRIs attenuates the response
to acute pain in newborns. When the heel lance was repeated
after 2 months, the pain response was still attenuated in SSRI
exposed infants (Oberlander et al., 2005). The attenuated pain
response may be due to increased 5-HT and GABA agonist levels
caused by SSRIs, as 5-HT and GABA agonists are known to play
a role in pain modulation and are active during early fetal neuro-
logic growth (Whitaker-Azmitia, 2001; Oberlander et al., 2002).
Zeskind and Stephens (2004) found that SSRI-exposed infants
displayed increased tremulousness, fewer changes in behavioral
state, fewer different behavioral states and greater amounts of
uninterrupted REM-sleep. Together, these results suggest that
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prenatal SSRI exposure has an effect which already appears early
after birth.
Although some studies exist, the long-term neurodevelopmen-
tal outcomes of prenatal SSRI exposure have not been extensively
studied. With regards to language development, Nulman et al.
(1997); Nulman et al. (2002) studied the IQ, temperament and
language development in children (16 and 86 months old) who
were exposed to SSRIs during pregnancy but did not find any
effects of prenatal SSRI exposure on the neurodevelopmental out-
comes measured. Prenatal SSRI exposure also appears to have no
effect on motor or speech development during the first 2 years of
life (Simon et al., 2002). Interestingly, Weikum et al. (2012) com-
pared infants of healthy mothers, with infants exposed to SSRIs
and infants exposed to antenatal depression and found that SSRI-
exposed infants showed accelerated perceptual development by
discriminating both vowels and consonants at 36 weeks gestation
(while in utero). These data indicate that SSRI-exposure may alter
the developmental time course of language perception.
However, there are several studies which describe an effect
of prenatal SSRI exposure on neurobehavioral outcomes.
Oberlander et al. (2007) studied externalizing behaviors (atten-
tion, aggression, attention/hyperactivity, and oppositional or
defiant behaviors) in 4 year olds and found that SSRI-exposed
children had greater externalizing scores than the clinical cutoff.
Data on internalizing behaviors is more conflicting. Whereas pre-
natal SSRI exposure and/or maternal depression have been asso-
ciated with increased internalizing behaviors (e.g., depression,
anxiety, withdrawal) in 3- and 4-year-old children (Oberlander
et al., 2010), other studies have found no such effects (Misri
et al., 2006). Additional studies report that 6–40 month old SSRI-
exposed children show mild effects on motor development and
control (tremulousness and fine motor movements), and lower
Psychomotor Developmental Index (PDI) scores on the Bayley
Scales of infant development (Casper et al., 2003). Mortensen
et al. (2003) studied psychomotor development in 7- to 10-
month-old children by means of the Boels test and found that
in children prenatally exposed to antidepressants (not specific for
SSRIs) had an increased risk for abnormal Boels test, indicating
that the risk for abnormal psychomotor development (such as
hearing, sight, and motor attention) is higher in children exposed
to antidepressants. Recently prenatal SSRI exposure, especially
during the first trimester, has been associated with an increased
risk for autism spectrum disorders (Croen et al., 2011). Together
these data suggest that prenatal SSRI exposure has effects on neu-
rodevelopmental outcomes, at birth and also later in childhood.
Stress regulation
Apart from its role in neurodevelopment, 5-HT is implicated in
the development and function of the HPA axis (Meaney et al.,
1994; Laplante et al., 2002; Andrews and Matthews, 2004) and
prenatal SSRI exposure has been suggested to affect aspects of
HPA function. Previous work has shown that prenatal SSRI expo-
sure results in attenuated basal salivary cortisol levels (Brennan
et al., 2008; Oberlander et al., 2008b) and attenuated facial action
and heart rate in response to an acute painful stressor in infants
(Oberlander et al., 2002, 2005). Corticosteroid binding globulin
(CBG), a transporter and regulator of circulating cortisol levels
(Siiteri et al., 1982), has been shown to be increased in SSRI-
exposed neonates, particularly after vaginal delivery (Pawluski
et al., 2012a). This increase in neonatal CBG levels was negatively
associated with diurnal changes in salivary cortisol at 3 months
of age. Furthermore, infants prenatally exposed to SSRIs have
lower evening basal cortisol levels and there are lower post-stress
cortisol levels in non-SSRI exposed and non-breastfed infants
compared with SSRI-exposed and non-SSRI exposed infants who
were breastfed at 3 months of age (Oberlander et al., 2008b).
These findings suggest that the effect of prenatal SSRI expo-
sure is present, but may only become apparent in a particular
maternal caregiving context (Hanley and Oberlander, 2012).
Serotonin transporter gene
The 5-HT transporter (5-HTT) plays a critical role in moderat-
ing environmental influences and developmental risks (Homberg
and Lesch, 2011). Humans carry a polymorphism in the pro-
moter region of the 5-HTT gene (5-HTTLPR), which involves a
common 44-base pair insertion/deletion of a repetitive sequence
(Lesch et al., 1996). The dominant short (S) allelic variant reduces
transcriptional efficiency of the SERT as compared with the
long (L) allelic variant (Lesch et al., 1996). Allelic variation of
5-HTTLPR may contribute to the responsiveness of SSRIs in
depressed patients. Pollock et al. (2000) showed that paroxetine
reduced depressive symptoms more rapidly in patients with the
LL genotype compared with S-allele carriers. Even early in life
allelic variation of the 5-HTTLPR can influence neonatal behav-
ior, especially in combination with environmental factors. For
example, when maternal anxiety levels were high, more negative
emotionality was found in infants carrying the S-allele, whereas
no effect of the 5-HTTLPR was found in circumstances with low
maternal anxiety (Pluess et al., 2011). Tiemeier et al. (2012) also
showed that the effect of maternal anxiety during fetal life and
early adulthood is moderated by the 5-HTTLPR of the child.
Children with the S-allele were at increased risk of developing
emotional problems and were less accurate in emotion-matching,
indicating affected ability to process emotions. Adults with two
S-alleles may be at increased risk for depression following early
life adversity (Caspi et al., 2003; Kendler et al., 2005; Lesch, 2007);
however, under positive environments S-allele carriersmight ben-
efit more compared to L-allele carriers. Hankin et al. (2011)
showed that positive parenting resulted in higher levels of posi-
tive affect in S-allele infants. These data are in agreement with the
theory of Belsky et al. (2009) who suggested that S-allele carri-
ers are more vulnerable in general, not only negatively, but also
positively. Thus, vulnerability genes, or risk alleles, seem to make
individuals more susceptible to environmental influences.
The combination of the allelic variation in 5-HTTLPR and
prenatal SSRI exposure may compound risks associated with
altered 5-HT levels. Recently an association was found, after pre-
natal SSRI exposure, between (1) SS-allele carriers and lower
5-min Apgar score and risk for neuromotor symptoms; (2)
LS-allele carriers and low birth weight; and (3) LL-allele carriers
and respiratory distress and tachypnea (Oberlander et al., 2008a).
In 3-year old SS-allele carriers, prenatal exposure to maternal
anxiety was associated with increased internalizing behaviors
and in 3-year old LL carriers, prenatal maternal anxiety was
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associated with more externalizing behaviors, regardless of pre-
natal SSRI exposure (Oberlander et al., 2010). Thus, 5-HTTLPR
genotype influences the effect of antenatal mood on child behav-
ior (Oberlander et al., 2010) and may modulate the outcome
of adverse neonatal effects following maternal SSRI exposure.
However, much more research is necessary to understand how
perinatal exposure to SSRIs affect developmental outcomes and
how these effects differ from the effects of exposure to perinatal
maternal mood disorders.
PRECLINICAL FINDINGS
In order to better understand the neurobehavioral and long-term
effects of perinatal exposure to SSRIs animal models have been
used. In particular, much research has investigated these effects
using rodents. At birth rats and mice are at a relative early stage
of maturation and their brain maturation occurs after birth. This
makes rodents highly suitable as a model for studying the direct
effects of SSRI exposure on early brain development. When rats
and mice are between 12 and 13 days old, the maturation of the
cerebral cortex is comparable to the human neocortex around
birth (Romijn et al., 1991; Homberg et al., 2010). The first and
second trimester of pregnancy in humans is comparable to the
prenatal period in rats, while the third trimester in humans is
comparable to the period right after birth (until PND12–13) in
rats. In the following studies both prenatal exposure and postnatal
exposure to SSRIs are described.
Pregnancy outcomes
SSRIs are able to cross the placenta in rodents at a similar trans-
fer rate to humans. Noorlander et al. (2008) exposed mice (i.p.
injection) from embryonic day (E)8–E16 of gestation with either
fluoxetine or fluvoxamine and collected blood plasma 5 h after
the last injection. The transfer rate of fluoxetine across the pla-
centa in mice (69%) was similar to the transfer rate of fluoxetine
across the placenta in women (73%). A lower placental transfer
rate was found for fluvoxamine in both mice (30%) and humans
(35%). When pregnant rats were injected daily with fluoxetine
from gestational day (G)11 until birth the placental transfer rate
5 h after the last injection was 83% for fluoxetine and 78% for
norfluoxetine (Olivier et al., 2011). The norfluoxetine/fluoxetine
ratio was 1.44 in mothers and 1.39 in pups, which is similar to
the ratios found in humans (Lundmark et al., 2001). SSRIs are
able to pass the blood brain barrier (Baumann and Rochat, 1995)
and this was confirmed in the study of Olivier et al. (2011). Both
fluoxetine and norfluoxetine have been detected in whole brain
samples of rat pups (Olivier et al., 2011). Although differences
exist between transfer rates of different SSRIs, they are trans-
ferred from mother to pup, altering both the periphery and the
central nervous systems. At the highest dose of fluoxetine tested
(0.8mg/kg/day), an 81% mortality rate was found after prena-
tal exposure, while fluvoxamine did not affect the survival rate in
mice (Noorlander et al., 2008). A 10-fold higher mortality rate
of neonatal rats was also found after prenatal paroxetine expo-
sure (van den Hove et al., 2008). Interestingly, rats that were
prenatally exposed to fluoxetine (12mg/kg/day; orally) from E11
until birth did not show increased mortality (Olivier et al., 2011).
However, litters that were prenatally exposed to fluoxetine were
smaller, therefore prenatal mortality is possible. Prenatal paroxe-
tine exposure in rats did not influence the litter size at birth, but
did reduce the gestational length and birth weight (van den Hove
et al., 2008). Prenatal fluoxetine exposure from E11 until birth
did not affect the gestational length, but did reduce the weight of
pups early after birth (Olivier et al., 2011). Interestingly, Vorhees
et al. (1994) have found increased neonatal mortality after prena-
tal fluoxetine exposure. Days of exposure and the use of different
rat strains may account for differences between studies. No effects
were found on long-term growth or survival (Vorhees et al., 1994;
Olivier et al., 2011). In conclusion, differences types of SSRIs,
doses, time-periods of SSRI exposure, and animal strains likely
influence the birth and neonatal outcomes.
Monoamine and biochemical concentrations
Prenatal exposure to fluoxetine from E11 to E21 significantly
reduced placental levels of 5-HT in rats (Fornaro et al., 2007).
Postnatal exposure to Zimelidine (SSRI) to rat pups 2–3 weeks
after birth significantly increased the 5-HIAA/5-HT ratio in
the brain stem and cortex of 2 month old offspring (Hilakivi
et al., 1995). In prenatally stressed mice, treatment with fluoxe-
tine during postnatal weeks 1–3 also lowered the 5-HT turnover
rate in offspring (Ishiwata et al., 2005). These data indicate
that the 5-HT metabolism is affected by early SSRI exposure
both in the periphery and the central nervous system. Limited
amounts of information are available on the biochemical profile
in rodents prenatally exposed to SSRIs. The neonatal behav-
ioral syndrome, which is often seen after withdrawal of SSRIs,
is associated with hypoglycemia (Favreliere et al., 2010). For this
reason Dubovický et al. (2012) studied glucose, lactate dehy-
drogenase, aspartate aminotransferase/alanine aminotransferase
ratio and antioxidant status in blood from prenatally (E15–
E20) venlafaxine-exposed (SNRI) rats. However they report no
differences between venlafaxine-exposed and non-exposed rat
offspring on postnatal day (PND)21.
Congenital malformations
A higher mortality rate has been found in neonatal rodents after
prenatal SSRI exposure (Noorlander et al., 2008; van den Hove
et al., 2008) and it has been postulated that heart malforma-
tions may be one reason for this increase in mortality. Noorlander
et al. (2008) found that the majority of fluoxetine-exposed off-
spring died postnatally because of severe dilated cardiomyopathy.
Moreover, the ratio of thickness of the left ventricle to the radius
of the left ventricle cavity was significantly decreased in prenatal
fluoxetine-exposed mouse offspring both at PND20 and dur-
ing adulthood. These data clearly show that prenatal fluoxetine
exposure (0.8mg/kg/day; i.p.) severely affects heart development,
resulting in an increased death rate in offspring. In vitro, (Sari
and Zhou, 2003) found that paroxetine significantly decreased
the rate of proliferation of fetal heart cells (E13) from rats, par-
ticularly cardiac myocytes and, to a lesser degree, non-muscle
cells. Fluoxetine and sertraline also have similar influences on
the proliferation of cardiac cells in the mouse embryo (Yavarone
et al., 1993). These data indicate that changes in prenatal 5-
HT levels influence the proliferation of the embryonic heart
cells, at least in vitro. Fluoxetine has furthermore been shown
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to affect cell viability and differentiation from undifferentiated
ES cells to cardiomyocytes in a dose-dependent manner. Analysis
of tissue-specific markers showed also that fluoxetine inhibits
mesodermal development but it promotes ectodermal differenti-
ation (Kusakawa et al., 2008). In another study, late two-cell stage
embryos incubated with fluoxetine for 6 h were more likely to
develop into blastocysts compared to the controls. Exposure to
fluoxetine for 24 h showed a reduction in blastocyst formation,
suggesting a time dependent effect of fluoxetine on blastocyst for-
mation. It also appears that these effects are, in part, due to altered
TREK signaling (Kim et al., 2012). In humans, the cardiomyocyte
proliferation is essentially complete at birth, whereas in rodents
cardiomyocyte growth and proliferation is robust for the first 14
days after birth (Clubb and Bishop, 1984; Walsh et al., 2010).
Haskell et al. (2012) injected mouse offspring with sertraline from
PND1 to PND14, reflecting the third trimester in humans, and
found that sertraline-exposed offspring showed increased heart
rate and activity levels, as well as smaller left ventricular inter-
nal diameters in diastole and decreased stroke volumes, indicating
changes in the cardiac morphology. Taken together, both in vitro
and in vivo early-exposure to SSRIs have adverse consequences for
the developmental outcomes of the heart.
Pulmonary hypertension
As far as we know, only one study has investigated the effects of
prenatal SSRI exposure on pulmonary hypertension in animal
models (Fornaro et al., 2007). Fluoxetine exposure during late
gestation resulted in abnormal oxygenation and a higher mortal-
ity rate in new-born rat pups compared to non-exposed controls.
Moreover, the right ventricular mass of the lung was higher in pre-
natal fluoxetine-exposed rats compared to controls. Interestingly
the effects seem to be sex-dependent; the right ventricular hyper-
trophy after prenatal fluoxetine exposure was only significant in
female pups (Belik, 2008). Moreover, the thickness of the medial
smooth muscle layer of the small and large pulmonary arteries
(used as magnitude of pulmonary vascular modeling) tended to
be thicker in the female, compared to male, pups. These sex-
differences in rats are interesting as the prevalence for PPHN in
humans is higher in male infants (Hernandez-Diaz et al., 2007).
Rodents that constitutively lack the 5-HTT could be seen as
a model for life-long SSRI exposure from conception. In 5-HTT
knockout (5-HTT−/−) mice that were exposed to hypoxia for
several weeks, the number and wall thickness of pulmonary ves-
sels decreased compared with controls (Eddahibi et al., 2000).
Moreover, compared with wild-type controls the right ventricu-
lar systolic pressure was lower and the right ventricle hypertrophy
was less hypertrophied in hypoxic 5-HTT−/− mice. In mice that
overexpress the 5-HTT (5-HTT+) there is a 3-fold increase in
right ventricle pressure compared to wild-type mice (MacLean
et al., 2004). Moreover, when 5-HTT+ mice were exposed to
hypoxia, right ventricular hypertrophy and pulmonary vascu-
lar remodeling were doubled compared to wild-types (MacLean
et al., 2004).
In summary, SSRI exposure during development increases the
risk for pulmonary hypertension in rodent models. Moreover,
overexpression of the 5-HTT from conception on increases the
risk, while disruption of the gene lowers the risk, for pulmonary
hypertension. It appears that the imbalance of the 5-HTT dur-
ing development contributes to the development of pulmonary
hypertension.
Neurodevelopmental outcomes
Prenatal fluoxetine exposure (G6–G20) has been reported to
cause a transient delay in motor development in rats on PND10
and PND12; decreased horizontal activity in an open arena on
PND8, but increased retention time on a rotating rod on PND22
and PND49 (Bairy et al., 2007). With respect to pain, the sensitiv-
ity in response to a hot-plate test on PND30, PND45, and PND70
was not altered by early fluoxetine exposure (G0-PND21) in mice
(Lisboa et al., 2007) or after fluoxetine exposure (PND1–21) in
8-week-old male rat offspring (Knaepen et al., 2013). However,
in adolescent rat offspring postnatal fluoxetine exposure (PND0–
PND6) did reduce pain sensitivity (Lee, 2009). Moreover, sen-
sorimotor learning deficits were found in adolescence offspring
exposed to fluoxetine, as well as reduced dendritic complexity of
thalamocortical afferents and in layer IV of the barrel cortex on
PND7 (Lee, 2009). In line with this, Xu et al. (2004) showed that
early postnatal paroxetine exposure (PND0–PND8) in rats dis-
rupts the organization of thalamocortical somatosensory barrels
on PND8. Recent work has also shown that adult male off-
spring exposed postnatally (PND1–21) to fluoxetine has increased
post-operative pain, measured as hypersensitivity to mechanical
stimuli after hind paw incision (Knaepen et al., 2013). However,
fluoxetine exposure to prenatally stressed offspring normalized
post-operative pain. This suggests that the actions of fluoxe-
tine likely differ in the presence of maternal adversity (Knaepen
et al., 2013). Taken together, these data suggest that early SSRI
exposure alters cortical development resulting in impaired trans-
mission of tactile information to the primary somatosensory
cortex.
Sleep-wakefulness patterns are also altered by early SSRI expo-
sure. Escitalopram exposure (PND5–PND19) increased REM-
sleep duration and decreased REM latency in mouse offspring
(Popa et al., 2008). In rat offspring, postnatal chlorimipramine
exposure (week 1–3) resulted into reduced active sleep, compen-
sated with quiet sleep (Mirmiran et al., 1981). Apart from altered
sleep patterns, chlorimipramine-exposed animals also performed
less efficiently on a temporal learning task but responded more
rapidly in a spatial alternation learning task. Prenatal expo-
sure to fluoxetine (G6–G20) increased cognitive performance;
fluoxetine-exposed rat offspring found a hidden platform in a
water maze faster compared with controls and had an increased
latency to enter a compartment where they previously received
a shock (Bairy et al., 2007). Using a model of prenatal stress,
Ishiwata et al. (2005) found that postnatal fluoxetine treatment
(postnatal weeks 1–3) to mouse offspring reduced the deficits in
spatial learning and memory seen after prenatal stress. Moreover,
postnatal SSRI exposure reversed the prenatal stress-induced
reduction in spine and synapse density in CA3 pyramidal cells
of the hippocampus (Ishiwata et al., 2005). As the learning ability
strongly correlates with the spine or synapse density in hippocam-
pal neurons, these data indicate that the increased synapse density
found after early fluoxetine exposure is the cellular basis of restor-
ing learning deficits induced by prenatal stress. Together these
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data indicate a favorable effect of early SSRI exposure on learning
and memory.
With respect to social and reproductive behaviors, early (G0
to PND21) fluoxetine exposure (Lisboa et al., 2007) as well
as postnatal (PND1–PND19) citalopram exposure (Manhães
de Castro et al., 2001) increased the latency to the first
attack of an intruder, indicating reduced aggression. Postnatal
treatment (PND8–PND21) with chlorimipramine, a tricyclic
antidepressant, clearly disturbed the performance of sexual
behavior inmale offspring with fewer mice ejaculating (Mirmiran
et al., 1981). The offspring that did ejaculate showed an
increased latency to the first ejaculation. Nevertheless, the
number of mounts and intromissions were similar between
groups, although the mount/intromission ratio was higher in
chlorimipramine-exposed animals indicating that these animals
were less efficient. Maciag et al. (2006) found that postnatal citalo-
pram exposure (PND8–PND21) significantly impaired mounting
behavior, reduced the number of intromissions and the number
of ejaculations. Interestingly, when rats were prenatally (G11 till
birth) exposed to fluoxetine no effects were found on the sexual
performance (Olivier et al., 2011). However, developmental flu-
oxetine treatment (PND1–21) decreased the anogenital distance
in juvenile male offspring, decreased the number of intromis-
sions, increased the latency to the first intromission, and increased
the latency to the first ejaculation in sexually naive male offspring
(Rayen et al., 2013). These effects were not evident if postnatal
fluoxetine exposure occurred after prenatal stress. Furthermore,
developmental fluoxetine and/or prenatal stress decreased the
area of the sexually dimorphic nucleus of the preoptic area (SDN-
POA) in these offspring (Rayen et al., 2013). Prenatal fluoxetine
exposure significantly affected juvenile play behavior and, dur-
ing adulthood, prenatal fluoxetine-exposed animals still tended to
make less contact with other rats (Olivier et al., 2011). Postnatal
exposure (PND8–PND21) to citalopram also decreased the inter-
est to play in male, but not female, juvenile rats (Simpson et al.,
2011). In conclusion, social and reproductive behaviors appear
to be most affected when 5-HT levels are disturbed during the
postnatal period in rodent models.
Affective behaviors in offspring are also altered by early SSRI
exposure. When rats were postnatally (PND8–PND21) exposed
to citalopram a neophobic response to an auditory stimulus,
as well as reduced exploration to a novel object, were found
(Simpson et al., 2011). In addition, citalopram exposure led to
abnormal myelin formation and a reduction in callosal connec-
tivity, indicating the importance of normal 5-HT homeostasis
for a proper maturation of the brain. Both prenatal (Bairy et al.,
2007; Olivier et al., 2011) and postnatal (Mirmiran et al., 1981;
Ansorge et al., 2004; Lisboa et al., 2007; Ansorge et al., 2008;
Popa et al., 2008; Simpson et al., 2011) SSRI exposure increased
anxiety-like behaviors in adult mice and rats. Also depression-like
behavior was increased after prenatal (Olivier et al., 2011) and
postnatal (Hansen et al., 1997; Lisboa et al., 2007; Popa et al.,
2008) SSRI exposure in adulthood. In adolescence, recent work
has shown that postnatal fluoxetine exposure (PND1–21) does
not significantly alter depressive-like behavior in male and female
rat offspring (Rayen et al., 2011). In addition, postnatal fluoxe-
tine exposure reversed effects of prenatal stress on depressive-like
behavior in adolescent offspring, thus normalizing this behav-
ior (Rayen et al., 2011). Similarly, postnatal fluoxetine exposure
reversed the effects of prenatal stress on hippocampal neuroge-
nesis in adolescence (Rayen et al., 2011). This suggests that the
long-term effects of fluoxetine may vary with age and previous
exposure to maternal stress.
The 5-HT1A receptor might be an important factor con-
tributing to the altered affective behaviors. During early brain
development, the 5-HT1A receptor is involved in neurite branch-
ing (Sikich et al., 1990), neurite outgrowth and neuronal survival
(Fricker et al., 2005). Moreover, 5-HT1A autoreceptors in raphe
5-HTergic neurons are important in regulating central 5-HT neu-
rotransmission by their negative feedback of 5-HT neuron firing.
Functional desensitization of the 5-HT1A autoreceptors is one of
the mechanisms that is thought to play a role in the therapeu-
tic action of SSRIs (Pineyro and Blier, 1999). Interestingly, both
prenatal (Olivier et al., 2011) and postnatal (Popa et al., 2008)
SSRI exposure increased the 5-HT1A agonist-induced hypother-
mia, indicating increased sensitivity of the 5-HT1A receptor.
Besides changes in the 5-HT1A receptor functioning, embryonic
SSRI exposure has also been shown to reduce 5-HTT expres-
sion (Hansen and Mikkelsen, 1998) and 5-HT2 receptor density
and function (Cabrera and Battaglia, 1994). Thus, early exposure
to SSRIs affects the 5-HTergic system, however, processes down-
stream of 5-HT receptors also mediate the neurotrophic effect
of 5-HT. Moreover epigenetic modifications may contribute to
developmental outcomes (Kinnally et al., 2010). Overall, early
exposure to SSRIs has an effect on brain development and neu-
roplasticity (for review see: Pawluski, 2012) which can markedly
alter the behavior of the offspring.
Stress regulation
Prenatal SSRI exposure has been shown to affect the developing
HPA system in animal models. For example, prenatal exposure
to fluoxetine increased cortisol levels in fetal lambs (Morrison
et al., 2004). Moreover, postnatal exposure to SSRIs decreased the
serum corticosterone levels and reduced the expression of CA3
hippocampal glucocorticoid receptor (GR) and its co-activator
GR interacting protein 1 (GRIP1) in adolescent rat offspring
(Pawluski et al., 2012b). These results were only found in male
adolescent offspring, indicating a sex difference in the neurode-
velopmental outcome. Postnatal exposure to fluoxetine (weeks
1–3) was also shown to reverse the effects of prenatal stress on
the corticosterone response to stress in adult mouse offspring
(Ishiwata et al., 2005). Postnatal fluoxetine exposure to prena-
tally stressed rats also increased CBG levels during adolescence,
suggesting significant alterations in circulating levels of free cor-
ticosterone (Pawluski et al., 2012b). Of interest is the fact that
these results were sex specific with long-term effects of combined
early-life stress and fluoxetine exposure on the HPA system exist-
ing only in male offspring. These sex differences are likely due
to differences in circulating sex steroid hormone levels, as estra-
diol has been shown to modulate the HPA system (Viau and
Meaney, 1991; Atkinson and Waddell, 1997; Viau, 2002). Much
more research is necessary to unravel the mechanisms underlying
these sex differences in HPA development and the role of steroid
hormones and monoamines in regulating these effects.
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Serotonin transporter gene
The polymorphism in the promoter of the 5-HTT is unique for
primates and not present in rodents (Caspi et al., 2010), but
the role of the 5-HTT has been extensively studied in rodent
models with genetic deletion of the 5-HTT (Murphy and Lesch,
2008; Kalueff et al., 2010; Homberg and Lesch, 2011). The phe-
notypes observed in these 5-HTT knockout (5-HTT−/−) rodents
mimic the long-term behavioral outcomes of early SSRI exposure.
5-HTT−/− rodents display reduced pain, exploratory behavior,
social behavior, and increased anxiety-like and depression-like
behavior (Kalueff et al., 2010). Moreover, 5-HTT−/− rodents
have improved cognitive performance (Brigman et al., 2010;
Nonkes et al., 2011; Van den Hove et al., 2011; Nonkes et al.,
2012). Regarding neuronal plasticity, SERT−/− rodents have
reduced brain-derived neurotrophic factor and activity-regulated
cytoskeleton associated protein expression levels in hippocam-
pus and prefrontal cortex (Molteni et al., 2009, 2010). Moreover,
neuronal PAS domain protein 4, regulating activity-dependent
genes and neuroprotection, is reduced in SERT−/− rodents and
this effect could be mimicked by prenatal fluoxetine exposure
(Guidotti et al., 2012). Reduced densities and functional alter-
ations of 5-HT receptors have been found in SERT−/− rats, as
well as changes in neurodevelopment (reviewed in: Kalueff et al.,
2010). The overlapping findings of life-long 5-HTT ablation and
early-life exposure to SSRIs in rodents suggest that neurodevel-
opmental changes are responsible for the phenotypes observed.
Therefore, the 5-HTT−/− model is of heuristic value in studying
the neurodevelopmental outcome of SSRI exposure.
CONCLUDING REMARKS
This review summarized clinical and preclinical findings of
how SSRI exposure during pregnancy affects child outcomes.
Although many clinical findings parallel aspects of the preclinical
data (Table 1), in preclinical studies SSRIs are often administered
to healthy animals, while in the clinic SSRIs are only adminis-
tered to depressed women. Moreover, preclinical models are often
tested during adulthood, whereas most clinical data comes from
children. These factors should be taken into account.
In addition there are often discrepancies between clinical
findings and this may be due the trimester when SSRIs are
taken, whether other medications were also administered, vari-
ety of other diagnoses (e.g., anxiety), the dose of the medica-
tion and the gestational age of the infant. In preclinical studies,
discrepancies between findings may be due to the timing of
SSRI exposure (prenatal or postnatal), the duration of expo-
sure, the dose administered and the SSRI used, as well as rodent
strain.
Both genetic and environmental factors contribute to the well-
being of a child. In humans, it is impossible to study the effects
of SSRI exposure without taking the underlying depression into
account. In animals, it is possible to disentangle the effects of
maternal depression from the effects of maternal SSRI exposure.
Moreover, the timing of maternal adversity and SSRI exposure
(duration and dosing) can be studied during the prenatal or post-
natal period or during both periods. The additional advantages of
using animal models are that one can readily examine long-term
neurodevelopmental outcomes, specific roles of maternal care,
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and neural plasticity. Unfortunately, most preclinical research
to date has studied the effects of SSRIs in healthy animals. In
order to make preclinical findings translational, it is important
to study the effects of SSRIs in a model of maternal depres-
sion or adversity, as the actions of developmental exposure to
SSRIs can significantly vary with exposure to maternal adversity.
Finally, preclinical studies reveal sexually dimorphic responses
which likely apply to humans as well. It is, therefore, important
to take the sex of the offspring into account.
It remains to be determined whether maternal SSRI use is
more beneficial or has adverse effects beyond the underlying
depression. Muchmore research is needed to understand the risks
and benefits of perinatal exposure to SSRIs on the developing
child. Future research should focus on the effects of maternal
depression alone, and compare it to offspring exposed to SSRIs,
and offspring exposed to SSRIs combined with maternal adver-
sity. Unraveling the different underlying mechanisms (which can
be environmental, genetic, or epigenetic) in these three different
groups will provide the answer for the risks and benefits of SSRI
use during pregnancy.
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